Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EntreMed has appointed Kenneth Bair as the new senior vice president of research and development. Dr Bair has also been elected an executive officer of EntreMed by the board of directors, reporting to James Burns, president and CEO.
Subscribe to our email newsletter
Dr Bair has over 25 years of management experience in oncology drug discovery, development and chemistry. Prior to joining EntreMed, Dr Bair served as senior vice president and head, BioPharmaceuticals Research at Chiron in Emeryville, California.
Dr Bair commented: “I am delighted to be joining the EntreMed team. The company has extensive scientific expertise in angiogenesis, cell cycle regulation, kinase inhibition and inflammation, which provide a strong foundation for building a leading oncology franchise.
“EntreMed’s pipeline of HIF-1a and kinase inhibitors fit well with my background and research interests. I look forward to leading the advancement of EntreMed’s mechanism-based drugs for the treatment of cancer and inflammatory diseases.”